A research team led by a Medical University of South Carolina (MUSC) investigator reports in the May 6 issue of the New England Journal of Medicine that a four-month treatment regimen using rifapentine is effective for treating TB. Shortening the treatment duration is an important step toward increased patient adherence. Read here
top of page
Recent Posts
See AllThis week, the WHO recommended four new treatments for patients with MDR-TB. Three of the regimens were from the End TB trial, and one...
130
The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to...
290
Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has...
200
bottom of page
Comments